Intervals from norgestomet withdrawal and injection of equine chorionic gonadotropin or P.G. 600 to estrus and ovulation in ewes.
Synchronization of estrus and ovulation is essential for AI of ewes during a predetermined time frame, and progestogen-eCG treatments are typically used to prepare the ewes. However, eCG is not readily available in the United States, but P.G. 600 (400 IU of eCG and 200 IU of hCG) is available. Thus, we conducted a study to determine the effects of eCG and P.G. 600 on the timing of estrus and ovulation after progestogen withdrawal. Ewes were assigned to two replicates of an experiment with the following treatments: 1) 3-mg norgestomet implant (i.e., one-half of a Syncro-Mate-B [SMB] implant) for 10 d, plus 2 mL of saline i.m. at SMB removal (n = 11); 2) 3-mg SMB implant for 10 d, plus 400 IU of eCG i.m. at SMB removal (n = 13); and 3) 3-mg SMB implant for 10 d, plus P.G. 600 i.m. at implant removal (n = 9). On d 6 after SMB insertion, PGF2alpha was used to induce luteolysis. Beginning 12 h after implant removal, vasectomized rams were used at 12-h intervals to check for estrus. When a ewe was detected in estrus, each ovary was evaluated ultrasonically. Ovaries were evaluated again 16 h later and then at 8-h intervals until ovulation. Treatment altered the interval from implant removal to estrus (less [P < 0.05] in SMB + eCG than in the other two groups) and to ovulation (greatest [P < 0.05] in SMB). However, the treatment x replicate interaction was significant for the intervals from implant removal to estrus (P < 0.03) and from implant removal to ovulation (P < 0.05). An inconsistent response in the SMB-treated ewes seemed to be primarily responsible for the interaction. The intervals to estrus and to ovulation for the SMB-treated ewes were shorter (P < 0.05) in Replicate 1 than in Replicate 2. Also, both intervals seemed to be less consistent between replicates for the SMB + P.G. 600- than for the SMB + eCG-treated ewes; that is, eCG seemed to increase the predictability of the intervals to estrus and to ovulation. Neither the main effects of treatment and replicate nor their interaction were significant for the interval from estrus to ovulation (38.4 /- 3.3 h), size of the ovulatory follicle (7.7 +/- 0.8 mm), or ovulation rate (1.6 +/- 0.2). We concluded from this experiment that eCG is a better choice than P.G. 600 as the gonadotropin to use at the time of progestogen withdrawal to prepare ewes for AI during a predetermined interval.
Department of Animal and Poultry Sciences, Virginia Polytechnic Institute and State University, Blacksburg 24061-0306, USA.
M A
MA
Cline
J N
JN
Ralston
R C
RC
Seals
G S
GS
Lewis
D000818:Animals; D006063:Chorionic Gonadotropin / Q000008:administration & dosage* / Q000494:pharmacology; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule / Q000662:veterinary*; D004338:Drug Combinations; D004971:Estrus / Q000187:drug effects*; D004973:Estrus Synchronization; D005260:Female; D006064:Gonadotropins, Equine / Q000008:administration & dosage* / Q000494:pharmacology; D010060:Ovulation / Q000187:drug effects*; D011282:Pregnenediones / Q000008:administration & dosage* / Q000494:pharmacology; D045167:Progesterone Congeners / Q000008:administration & dosage* / Q000494:pharmacology; D012756:Sheep / Q000502:physiology*
D006063:Chorionic Gonadotropin; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D006064:Gonadotropins, Equine; D011282:Pregnenediones; D045167:Progesterone Congeners; C100284:norgestomet; C006116:chorionic gonadotropin, pregnant mare serum gonadotropin drug combination